MIC and time-kill study of activities of DU-6859a, ciprofloxacin, levofloxacin, sparfloxacin, cefotaxime, imipenem, and vancomycin against nine penicillin-susceptible and -resistant pneumococci
about
Structure-activity relationships of Bacillus cereus and Bacillus anthracis dihydrofolate reductase: toward the identification of new potent drug leadsAntipneumococcal activities of levofloxacin and clarithromycin as determined by agar dilution, microdilution, E-test, and disk diffusion methodologies.Postantibiotic effect and postantibiotic sub-MIC effect of levofloxacin compared to those of ofloxacin, ciprofloxacin, erythromycin, azithromycin, and clarithromycin against 20 pneumococciAntipneumococcal activity of grepafloxacin compared to that of other agents by time-kill methodology.Management of infections due to antibiotic-resistant Streptococcus pneumoniaeAntipneumococcal activities of gemifloxacin compared to those of nine other agentsActivities and postantibiotic effects of gemifloxacin compared to those of 11 other agents against Haemophilus influenzae and Moraxella catarrhalisIn vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8,796 clinical bacterial isolates.Activities of newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.In vivo efficacies and pharmacokinetics of DX-619, a novel des-fluoro(6) quinolone, against Streptococcus pneumoniae in a mouse lung infection model.In vitro pharmacodynamic activities of ABT-492, a novel quinolone, compared to those of levofloxacin against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalisMIC and time-kill study of antipneumococcal activities of RPR 106972 (a new oral streptogramin), RP 59500 (quinupristin-dalfopristin), pyostacine (RP 7293), penicillin G, cefotaxime, erythromycin, and clarithromycin against 10 penicillin-susceptibleMIC and time-kill studies of antipneumococcal activity of GV 118819X (sanfetrinem) compared with those of other agentsTrovafloxacin, a new fluoroquinolone with potent activity against Streptococcus pneumoniae.Bactericidal activity of DU-6859a compared to activities of three quinolones, three beta-lactams, clindamycin, and metronidazole against anaerobes as determined by time-kill methodology.Comparison of the postantibiotic and postantibiotic sub-MIC effects of levofloxacin and ciprofloxacin on Staphylococcus aureus and Streptococcus pneumoniae.In vitro synergism between cefotaxime and minocycline against Vibrio vulnificus.Antipneumococcal activity of BMS 284756 compared to those of six other agents.Antipneumococcal activity of ertapenem (MK-0826) compared to those of other agents.Antipneumococcal and antistaphylococcal activities of ranbezolid (RBX 7644), a new oxazolidinone, compared to those of other agents.Antipneumococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents.Antipneumococcal activity of DK-507k, a new quinolone, compared with the activities of 10 other agents.Antipneumococcal activity of dalbavancin compared to other agents.In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococciAntipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agentsAntipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin.Comparative antipneumococcal activities of sulopenem and other drugs.
P2860
Q24673580-B8B31BF0-3EAE-41E8-A8C6-8FE66AF017B5Q33685617-4F287534-8412-47BF-9883-499336AEAB38Q33696032-72B2A660-A30F-4AF6-975D-59A8D5ADE62AQ33696166-828886B3-E2CD-4724-BC15-06AEB8E009E2Q33975374-FAD877C8-C7FA-4C83-9B35-203D9DB71DA0Q33978679-CAE0516D-7331-4E0D-B66F-F5E6F3C154FEQ33978946-EEACE8B2-8507-45B7-8C4E-35103FDDB380Q33979294-DB625B25-1297-4E5A-B390-9B7EE86DA35EQ33982211-EFE9C93D-94D0-40A0-B101-F05366F0D71BQ34301493-EFE657A8-DB62-4047-9FCC-E201FCB5B895Q35005817-7911EF20-70FE-45E9-9E2E-1D10EDD295B0Q35126660-5A6826BC-5888-48DB-B149-16376451222BQ35131455-36EE06F5-548B-49A0-AE59-448771FE8170Q35133005-ECAB317B-B6A2-42AF-9F17-E1D2DC21C4CAQ35135289-E9114D94-A854-4FA5-B0BC-6A7ADD681722Q35135800-FEB9F1D5-1004-4448-9D66-088809427C92Q35138554-BF166BA8-D48E-4892-B602-E2E141AAC67AQ39650891-24003FD2-5AE6-45BA-AAC6-D676CCAA32CAQ39650917-EB39D52E-4E24-45D6-B414-949FAF03ACC7Q39732005-5C01498E-42CC-4B5B-9686-6664D67DDD23Q40165383-22E5B8B5-DD3F-4CEB-83F1-9EB6FD87B9D1Q40345358-C477C2AA-8866-49E9-9946-39F465C52DC2Q40668272-C58873A7-F2C7-4769-8BEE-7B5720A530DBQ41825665-61CFE35A-ACA3-4915-B392-321A56CAE71FQ42112427-59A34C4C-B4BC-4305-851E-D3B2468E9E99Q42112713-C0184457-1F3E-4F31-A489-D9CE49CF5408Q43121857-E6BD3CB7-A702-48BA-A706-FBE3830CC6B5
P2860
MIC and time-kill study of activities of DU-6859a, ciprofloxacin, levofloxacin, sparfloxacin, cefotaxime, imipenem, and vancomycin against nine penicillin-susceptible and -resistant pneumococci
description
1996 nî lūn-bûn
@nan
1996 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
MIC and time-kill study of act ...... ble and -resistant pneumococci
@ast
MIC and time-kill study of act ...... ble and -resistant pneumococci
@en
type
label
MIC and time-kill study of act ...... ble and -resistant pneumococci
@ast
MIC and time-kill study of act ...... ble and -resistant pneumococci
@en
prefLabel
MIC and time-kill study of act ...... ble and -resistant pneumococci
@ast
MIC and time-kill study of act ...... ble and -resistant pneumococci
@en
P2093
P2860
P1476
MIC and time-kill study of act ...... ble and -resistant pneumococci
@en
P2093
Appelbaum PC
Visalli MA
P2860
P304
P407
P577
1996-02-01T00:00:00Z